We are live on
!
Find out more
CIC
Cornercap Investment Counsel Portfolio holdings
AUM
$203M
1-Year Est. Return
17.67%
This Fund
S&P 500
This Quarter
Est. Return
+2.8%
1 Year Est. Return
+17.67%
3 Year Est. Return
+55.44%
5 Year Est. Return
+79.88%
10 Year Est. Return
+193.02%
AUM
$575M
AUM Growth
+$7.13M
(+1.3%)
Cap. Flow
-$3.73M
Cap. Flow
% of AUM
-0.65%
Top 10 Holdings %
Top 10 Hldgs %
8.61%
Holding
700
New
139
Increased
152
Reduced
171
Closed
133
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Walt Disney
DIS
|
+$3M |
| 2 |
Paycom
PAYC
|
+$2.19M |
| 3 |
Salesforce
CRM
|
+$2.04M |
| 4 |
PPG Industries
PPG
|
+$2.01M |
| 5 |
Walmart Inc
WMT
|
+$1.99M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Wells Fargo
WFC
|
+$3.36M |
| 2 |
Comcast
CMCSA
|
+$3.32M |
| 3 |
AbbVie
ABBV
|
+$2.94M |
| 4 |
Amgen
AMGN
|
+$2.18M |
| 5 |
DFS
Discover Financial Services
DFS
|
+$1.94M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.22% |
| 2 | Financials | 16.95% |
| 3 | Healthcare | 13.98% |
| 4 | Industrials | 13.52% |
| 5 | Consumer Discretionary | 9.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
501
Nuvation Bio
NUVB
$2.32B
| $215K | 0.04% |
119,285
| – | – |
|
502
Cue Biopharma
CUE
$114M
| $214K | 0.04% |
+1,955
| New | +$230K |
|
503
Beam Therapeutics
BEAM
$2.84B
| $212K | 0.04% |
+6,655
| New | +$216K |
|
|
GBIO
504
DELISTED
Generation Bio
GBIO
| $209K | 0.04% |
3,806
+939
| +33% | +$43.1K |
|
505
Builders FirstSource
BLDR
$8.04B
| $207K | 0.04% |
+1,524
| New | +$169K |
|
|
KNTE
506
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $206K | 0.04% |
+68,040
| New | +$262K |
|
507
Tenaya Therapeutics
TNYA
$163M
| $205K | 0.04% |
+34,847
| New | +$203K |
|
508
Kraft Heinz
KHC
$30B
| $203K | 0.04% |
5,713
-803
| -12% | -$30.9K |
|
509
Dollar Tree
DLTR
$25.2B
| $203K | 0.04% |
1,412
-52
| -4% | -$7.65K |
|
510
Cullinan Oncology
CGEM
$1.14B
| $202K | 0.04% |
18,795
+2,856
| +18% | +$30.3K |
|
|
DFTX
511
Definium Therapeutics
DFTX
$6.12B
| $202K | 0.04% |
+56,478
| New | +$195K |
|
512
Evercore
EVR
$11.8B
| $201K | 0.04% |
+1,630
| New | +$188K |
|
513
D.R. Horton
DHI
$42.3B
| $201K | 0.04% |
+1,653
| New | +$181K |
|
514
Eli Lilly
LLY
$1.06T
| $200K | 0.03% |
+427
| New | +$179K |
|
515
Fate Therapeutics
FATE
$326M
| $199K | 0.03% |
41,863
| – | – |
|
516
Edgewise Therapeutics
EWTX
$4.73B
| $195K | 0.03% |
25,107
-6,797
| -21% | -$57.3K |
|
517
Pyxis Oncology
PYXS
$236M
| $194K | 0.03% |
+75,905
| New | +$241K |
|
518
Monte Rosa Therapeutics
GLUE
$1.35B
| $193K | 0.03% |
28,192
| – | – |
|
519
MacroGenics
MGNX
$257M
| $191K | 0.03% |
35,733
-15,748
| -31% | -$97.1K |
|
520
Nurix Therapeutics
NRIX
$2.65B
| $187K | 0.03% |
18,756
| – | – |
|
521
Atara Biotherapeutics
ATRA
$76.1M
| $187K | 0.03% |
+4,646
| New | +$263K |
|
522
BioAtla
BCAB
$5.74M
| $185K | 0.03% |
1,231
| – | – |
|
523
Foghorn Therapeutics
FHTX
$360M
| $184K | 0.03% |
26,163
| – | – |
|
|
KZR
524
DELISTED
Kezar Life Sciences
KZR
| $183K | 0.03% |
+7,457
| New | +$194K |
|
|
LENZ
525
LENZ Therapeutics
LENZ
$168M
| $173K | 0.03% |
9,490
| – | – |
|
Similar funds
NWM
MAM
EECFX
PSB
HIA
NMG
EECFX
BC
Cornercap Investment Counsel's Q2 2023 Portfolio in Review
As of Q2 2023, Cornercap Investment Counsel held 700 positions worth $575M, up 1.3% from $568M the previous quarter. Its ten largest holdings account for 8.6% of the portfolio.
Cornercap Investment Counsel's Q2 2023 filing shows 139 new, 152 increased, 171 reduced and 133 closed positions. Its largest new stake was Walt Disney: 31,661 shares worth $2.83M. The largest sale was Wells Fargo, an estimated $3.36M.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 16% a quarter earlier, followed by Financials and Healthcare.
- Cornercap Investment Counsel's largest Q2 2023 buy was Walt Disney: 31,661 shares worth $2.83M.
- Cornercap Investment Counsel added most to MSCI in Q2 2023, an estimated $1.63M increase.
- Cornercap Investment Counsel's biggest Q2 2023 reduction was Edwards Lifesciences, cutting an estimated $1.86M.
- Cornercap Investment Counsel fully exited Wells Fargo in Q2 2023, selling an estimated $3.36M.
- Cornercap Investment Counsel's ten largest holdings make up 8.6% of its $575M portfolio in Q2 2023.
- Cornercap Investment Counsel opened 139 new positions and closed 133 in Q2 2023.
- Cornercap Investment Counsel's portfolio value rose 1.3% quarter-over-quarter to $575M.
Based on Cornercap Investment Counsel's 13F filing for Q2 2023, filed 11 Aug 2023.